BMJ analysis warns UK-US pharma deal risks 229,000 excess deaths in England by 2036
The UK-US pharmaceuticals deal will force the NHS to spend an extra £44.7 billion on branded medicines by 2036 without additional funding.
The UK-US pharmaceuticals deal will force the NHS to spend an extra £44.7 billion on branded medicines by 2036 without additional funding.
Researchers recorded approximately 2,700 excess deaths in England and Wales from the May and June 2026 heatwaves, over 40 percent linked to climate change.